Li C - Search Results

1

Nuclear EGFR contributes to acquired resistance to cetuximab.

Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Li C, et al. Oncogene. 2009 Oct 29;28(43):3801-13. doi: 10.1038/onc.2009.234. Epub 2009 Aug 17. Oncogene. 2009. PMID: 19684613 Free PMC article.

2

Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma.

Li C, Iida M, Dunn EF, Wheeler DL. Li C, et al. Radiother Oncol. 2010 Nov;97(2):330-7. doi: 10.1016/j.radonc.2010.06.010. Radiother Oncol. 2010. PMID: 20667610 Free PMC article.

3

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.

Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL. Dunn EF, et al. Among authors: li c. Oncogene. 2011 Feb 3;30(5):561-74. doi: 10.1038/onc.2010.430. Epub 2010 Oct 18. Oncogene. 2011. PMID: 20956938 Free PMC article.

4

Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.

Brand TM, Dunn EF, Iida M, Myers RA, Kostopoulos KT, Li C, Peet CR, Wheeler DL. Brand TM, et al. Among authors: li c. Cancer Biol Ther. 2011 Sep 1;12(5):436-46. doi: 10.4161/cbt.12.5.16394. Epub 2011 Sep 1. Cancer Biol Ther. 2011. PMID: 21725209 Free PMC article.

5

p53 modulates acquired resistance to EGFR inhibitors and radiation.

Huang S, Benavente S, Armstrong EA, Li C, Wheeler DL, Harari PM. Huang S, et al. Among authors: li c. Cancer Res. 2011 Nov 15;71(22):7071-9. doi: 10.1158/0008-5472.CAN-11-0128. Epub 2011 Nov 8. Cancer Res. 2011. PMID: 22068033 Free PMC article.

6

The nuclear epidermal growth factor receptor signaling network and its role in cancer.

Brand TM, Iida M, Li C, Wheeler DL. Brand TM, et al. Among authors: li c. Discov Med. 2011 Nov;12(66):419-32. Discov Med. 2011. PMID: 22127113 Free PMC article. Review.

7

Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor.

Iida M, Brand TM, Campbell DA, Li C, Wheeler DL. Iida M, et al. Among authors: li c. Oncogene. 2013 Feb 7;32(6):759-67. doi: 10.1038/onc.2012.90. Epub 2012 Mar 19. Oncogene. 2013. PMID: 22430206 Free PMC article.

8

Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.

Huang S, Li C, Armstrong EA, Peet CR, Saker J, Amler LC, Sliwkowski MX, Harari PM. Huang S, et al. Among authors: li c. Cancer Res. 2013 Jan 15;73(2):824-33. doi: 10.1158/0008-5472.CAN-12-1611. Epub 2012 Nov 20. Cancer Res. 2013. PMID: 23172311 Free PMC article.

9

Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma.

Li C, Brand TM, Iida M, Huang S, Armstrong EA, van der Kogel A, Wheeler DL. Li C, et al. Discov Med. 2013 Sep;16(87):79-92. Discov Med. 2013. PMID: 23998444 Free PMC article.

10

Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers.

Huang S, Peet CR, Saker J, Li C, Armstrong EA, Kragh M, Pedersen MW, Harari PM. Huang S, et al. Among authors: li c. Mol Cancer Ther. 2013 Dec;12(12):2772-81. doi: 10.1158/1535-7163.MCT-13-0587. Epub 2013 Oct 15. Mol Cancer Ther. 2013. PMID: 24130052 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

89,108 results

Search Page

Filters